The quantitative LumiraDx D-Dimer Test provides lab-comparable results at the point of care

Performance Evaluation of the Quantitative Point-of-Care LumiraDx D-Dimer Test

Cardiology and Therapy

A point-of-care (POC) quantitative D-Dimer test could improve the effectiveness of the established diagnosis pathway of venous thromboembolism (VTE), thereby reducing the current rate of unnecessary referrals to secondary care along with associated cost and improve patient experience.

The primary aim of this study was to assess the performance of the new point of care quantitative LumiraDx D-Dimer Test for accuracy, precision, and measurement repeatability across several sample types, including fingerstick capillary blood, compared to established, laboratory-based analysis.

The quantitative LumiraDx D-Dimer Test was able to accurately measure D-Dimer levels using samples across the range 60µg /l and 4515µg/l fibrinogen equivalent units (FEU), with a low error rate across a range of blood sample types.

The quantitative D-Dimer test was shown to be easy to use by users in POC settings.

The study results show that this novel quantitative POC test provides accurate results at the point of care when patients are presenting with symptoms of VTE and a quantitative D-Dimer test is quickly needed. When utilized in line with the diagnostic guidance, this could facilitate more accurate referrals for imaging diagnostics of VTE in settings such as primary care, where most patients initially present.


Supporting healthier lives, for individuals, communities and wider society.

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.

Be Informed